Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma

Redox Biology

Volumn 1, Issue 1, 2013, Pages 285-291

  Woolston, Caroline M ^a   Madhusudan, Srinivasan ^a   Soomro, Irshad N ^b   Lobo, Dileep N ^b   Reece Smith, Alexander M ^b   Parsons, Simon L ^b   Martin, Stewart G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Chemotherapy; Gastric cancer; Predictive; Prognostic; Redox; Thioredoxin interacting protein

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; THIOREDOXIN INTERACTING PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; REACTIVE OXYGEN METABOLITE; TXNIP PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERINEURAL INVASION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH SURGERY; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84899519471     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.04.006     Document Type: Article

References (37)

1. D. Cunningham, W.H. Allum, S.P. Stenning, et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, New England Journal of Medicine 355 (2006) 11-20.
2. Medical Research Council Oesophageal Cancer Working Group, Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial, Lancet 359 (2002) 1727-1733
3. W. Li, J. Qin, Y.-H. Sun, T.-S. Liu, Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis, World Journal of Gastroenterology 16 (2010) 5621-5628.
4. D. Cunningham, N Starling, S. Rao, et al., Capecita bine and oxaliplatin for advanced esophagogastric cancer, New England Journal of Medicine 358 (2008) 36-46.
5. H. Masuda, T. Tanaka, U. Takahama, Cisplatin generates superoxide anion by interaction with DNA in a cell-free system, Biochemical and Biophysical Research Communications 203 (1994) 1175-1180.
6. K. Sugihara, M. Gemba, Modification of cisplatin toxicity by antioxidants, Japanese Journal of Pharmacology 40 (1986) 353-355.
7. T. Sasada, H. Nakamura, S. Ueda, et al., Secretion of thioredoxin enhances cellular resistance to cis-diamminedichloroplatinum(II), Antioxid Redox Signaling 2 (2000) 695-705.
8. I. Muller, D. Niethammer, G. Bruchelt, Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (review), International Journal of Molecular Medicine 1 (1998) 491-494.
9. A Ravid, D. Rocker, A. Machlenkin, et al., 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage, Cancer Research 59 (1999) 862-867.
10. J.D. Pennington, T.J. Wang, P. Nguyen, et al., Redox-sensitive signalling factors as a novel molecular targets for cancer therapy, Drug Resistance Updates 8 (2005) 322-330.
11. M. Valko, D. Leibfritz, J. Moncol, M.T.D. Cronin, M. Mazur, J. Telser, Free radicals and antioxidants in normal physiological functions and human disease, International Journal of Biochemistry and Cell Biology 39 (2007) 44-84.
12. A. Mukherjee, S.G. Martin, The thioredoxin system: a key target in tumour and endothelial cells, British Journal of Radiology 81 (2008) S57-S68.
13. CM Woolston, S.J. Storr, I.O. Ellis, D.A. Morgan, S.G. Martin, Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer, Radiotherapy Oncology 100 (2011) 308-313.
14. S.H. Han, J.H. Jeon, H.R. Ju, et al., VDUP1 upregulated by TGF-β1 and 1,25-dihydroxyvitamin D3 inhibits tumour cell growth by blocking cell-cycle progression, Oncogene 22 (2003) 4035-4046.
15. L.M. Butler, X. Zhou, W.S. Xu, et al., The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin, Proceedings of the National Academy of Sciences USA 99 (2002) 11700-11705.
16. M. Ikarashi, Y. Takahashi, Y. Ishii, T. Nagata, S. Asai, K. Ishikawa, Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease, Anticancer Research 22 (2002) 4045- 4048.
17. C.M. Woolston, L. Zhang, S.J. Storr, et al., The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer, Modern Pathology (2012), http://dx.doi.org/10.1038/modpathol.2012.60.
18. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, G.M. Clark, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumour marker prognostic studies, Journal of Clinical Oncology 23 (2005) 9067-9072.
19. S.J. Storr, X. Pu, J. Davis, D. Lobo, et al., Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas, Journal of Gastroenterology (2013), PMID:23329366 [Epub ahead of print].
20. A.M. Mandard, F. Dalibard, J.C. Mandard, et al., Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations, Cancer 73 (1994) 2680-2686.
21. J. Kononen, L. Bubendorf, A. Kallioniemi, et al., Tissue microarrays for highthroughput molecular profiling of tumour specimens, Nature Medicine 4 (1998) 844-847.
22. C.M. Woolston, S. Deen, A. Al-Attar, M. Shehata, S.Y. Chan, S.G. Martin, Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy, Free Radical Biology and Medicine 49 (2010) 1263-1272.
23. J.Y. Lim, S.O. Yoon, S.W. Hang, J.W. Kim, S.H. Choi, J.Y. Cho, Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence, World Journal of Gastroenterology 18 (2012) 5581-5588.
24. Y. Takahashi, T. Nagata, Y. Ishii, M. Ikarashi, K. Ishikawa, S. Asai, Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620, Oncology Reports 9 (2002) 75-79.
25. I.T. Hwang, Y.M. Chung, J.J. Kim, et al., Drug resistance to 5-FU linked to reactive oxygen species modulator 1, Biochemical and Biophysical Research Communications 359 (2007) 304-310.
26. B Ho, G Huang, VM. Golubovskaya, Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TxNIP) in cancer cells, Anticancer Agents in Medicinal Chemistry (2013), PMID:23387972 [Epub ahead of print].
27. J. Yoshioka, P.C. Schulze, M. Cupesi, et al., Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity, Circulation 109 (2004) 2581-2586.
28. E. Junn, S.H. Han, J.Y. Im, et al., Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function, Journal of Immunology 164 (2000) 6287-6295.
29. H. Song, D. Cho, J.H. Jeon, et al., Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species, Immunology Letters 86 (2003) 235-247.
30. T.M. Grogan, C. Fenoglio-Prieser, R. Zeheb, et al., Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival, Human Pathology 31 (475) (2000) 481.
31. H.J. Kwan, Y.S. Won, K.T. Nam, et al., Vitamin D3 upregulated protein 1 deficiency promotes N-methyl-N-nitrosourea and Helicobacter pyloriinduced gastric carcinogenesis in mice, Gut 61 (2012) 53-63.
32. J.H. Lee, E.G. Jeong, M.C. Choi, et al., Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells, Molecules and Cells 30 (2010) 107-112.
33. S.F. Goldberg, M.E. Miele, N. Hatta, et al., Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP, Cancer Research 63 (2003) 432-440.
34. D. Shin, J.H. Jeon, M. Jeong, et al., VDUP1 mediates nuclear export of HIF1α via CRM1-dependent pathway, Biochimica et Biophysica Acta 1783 (2008) 838-848.
35. S.S. Sheth, J.S. Bodnar, A. Ghazalpour, et al., Hepatocellular carcinoma in Txnip-deficient mice, Oncogene 25 (2006) 3528-3536.
36. Y Takahashi, Y. Ishii, A. Murata, T. Nagata, S. Asai, Localization of thioredoxininteracting protein (TxNIP) mRNA in epithelium of human gastrointestinal tract, Journal of Histochemistry and Cytochemistry 51 (2003) 973-976.
37. N. Noda, A. Ochiai, K. Miyazaki, T. Sugimura, M. Terada, H.Wakasugi, Detection of thioredoxin in gastric cancer: association with histological type, Antioxidants and Redox Signaling 2 (2000) 519-528.